These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
560 related articles for article (PubMed ID: 29892259)
1. Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy. André LM; Ausems CRM; Wansink DG; Wieringa B Front Neurol; 2018; 9():368. PubMed ID: 29892259 [TBL] [Abstract][Full Text] [Related]
2. Muscle wasting in myotonic dystrophies: a model of premature aging. Mateos-Aierdi AJ; Goicoechea M; Aiastui A; Fernández-Torrón R; Garcia-Puga M; Matheu A; López de Munain A Front Aging Neurosci; 2015; 7():125. PubMed ID: 26217220 [TBL] [Abstract][Full Text] [Related]
3. Intrinsic Myogenic Potential of Skeletal Muscle-Derived Pericytes from Patients with Myotonic Dystrophy Type 1. Ausems CRM; Raaijmakers RHL; van den Broek WJAA; Willemse M; van Engelen BGM; Wansink DG; van Bokhoven H Mol Ther Methods Clin Dev; 2019 Dec; 15():120-132. PubMed ID: 31649961 [TBL] [Abstract][Full Text] [Related]
4. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Meola G Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of muscle atrophy in myotonic dystrophies. Timchenko L Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888 [TBL] [Abstract][Full Text] [Related]
7. Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism. Meola G; Cardani R J Neuromuscul Dis; 2015 Jul; 2(s2):S59-S71. PubMed ID: 27858759 [TBL] [Abstract][Full Text] [Related]
8. Myotonic Dystrophies: A Genetic Overview. Soltanzadeh P Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205411 [TBL] [Abstract][Full Text] [Related]
9. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2. Timchenko L Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405 [TBL] [Abstract][Full Text] [Related]
10. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds. Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264 [TBL] [Abstract][Full Text] [Related]